• The first patient was treated with Sunitinib following the occurrence of multiple soft-tissue and lung metastases
• After 12 mo of follow-up, despite no reduction in the size of the metastases, the contrast enhancement was lower and patient’s symptoms had resolved. Increased hypertension was effectively managed using antihypertensive treatment, and no dose reductions were required
• The second case had synchronous multiple liver metastases and received sunitinib as a firstline treatment
• After 13 mo, a partial response was achieved with minimal toxicity. Adverse events observed included grade 1 diarrhea and grade1/2 hand-foot syndrome
• No sunitinib dose reductions were required. In addition, the patient reported improvements in quality of life
Copyright © 